May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement  for the continued Phase III development and worldwide commercialization of flurpiridaz F-18.

Registration has opened for the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), which will highlight advances in cancer research and clinical care involving radiation therapy. The meeting, which will be held Sept. 24–27 at the San Diego Convention Center, is expected to attract more than 11,000 attendees from across the globe, including oncologists from all disciplines and members of the entire radiation oncology team.

Partners HealthCare and GE Healthcare announced a 10-year collaboration to rapidly develop, validate and strategically integrate deep learning technology across the entire continuum of care. The collaboration will be executed through the newly formed Massachusetts General Hospital and Brigham and Women’s Hospital Center for Clinical Data Science and will feature co-located, multidisciplinary teams with broad access to data, computational infrastructure and clinical expertise.

May 17, 2017 — Tumors, inflammation and circulatory disorders locally disturb the body's acid-base balance. These changes in pH value could be used for example to verify the success of cancer treatments. Up to now, however, there has been no imaging method to render such changes visible in patients.

Proton International announced the successful financing of a new state-of-the-art radiation therapy center and a pioneering approach to proton center financing provided and coordinated by Loop Capital.